MX384379B - Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-fármaco. - Google Patents
Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-fármaco.Info
- Publication number
- MX384379B MX384379B MX2017002600A MX2017002600A MX384379B MX 384379 B MX384379 B MX 384379B MX 2017002600 A MX2017002600 A MX 2017002600A MX 2017002600 A MX2017002600 A MX 2017002600A MX 384379 B MX384379 B MX 384379B
- Authority
- MX
- Mexico
- Prior art keywords
- stability
- drug conjugates
- antibody
- modulating
- linkers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a conjugados anticuerpo-fármaco de estabilidad modulada, componentes ligadores que modulan la estabilidad utilizados para fabricar los conjugados anticuerpo-fármaco de estabilidad modulada, métodos terapéuticos que usan conjugados anticuerpo-fármaco de estabilidad modulada, y métodos para fabricar los ligadores que modulan la estabilidad y los conjugados anticuerpo-fármaco de estabilidad modulada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462042901P | 2014-08-28 | 2014-08-28 | |
| PCT/IB2015/056211 WO2016030791A1 (en) | 2014-08-28 | 2015-08-14 | Stability-modulating linkers for use with antibody drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017002600A MX2017002600A (es) | 2017-05-19 |
| MX384379B true MX384379B (es) | 2025-03-14 |
Family
ID=54266589
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017002600A MX384379B (es) | 2014-08-28 | 2015-08-14 | Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-fármaco. |
| MX2021008334A MX2021008334A (es) | 2014-08-28 | 2017-02-27 | Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008334A MX2021008334A (es) | 2014-08-28 | 2017-02-27 | Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10967068B2 (es) |
| EP (1) | EP3185908B1 (es) |
| JP (2) | JP6832621B2 (es) |
| KR (1) | KR102051503B1 (es) |
| CN (1) | CN106795203B (es) |
| AU (1) | AU2015308179B2 (es) |
| CA (1) | CA2901684C (es) |
| DK (1) | DK3185908T3 (es) |
| ES (1) | ES2797754T3 (es) |
| HU (1) | HUE049325T2 (es) |
| IL (1) | IL250319B (es) |
| MX (2) | MX384379B (es) |
| PL (1) | PL3185908T3 (es) |
| PT (1) | PT3185908T (es) |
| RU (1) | RU2680238C2 (es) |
| SI (1) | SI3185908T1 (es) |
| WO (1) | WO2016030791A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| EP3419670A2 (en) | 2016-02-26 | 2019-01-02 | Regeneron Pharmaceuticals, Inc. | Optimized transglutaminase site-specific antibody conjugation |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| EP3455241B1 (en) | 2016-05-11 | 2022-02-23 | Cytiva BioProcess R&D AB | Method of cleaning and/or sanitizing a separation matrix |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| WO2017194592A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of storing a separation matrix |
| JP7122974B2 (ja) | 2016-05-11 | 2022-08-22 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 変異免疫グロブリン結合ポリペプチド |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| JP2018058822A (ja) | 2016-08-03 | 2018-04-12 | ファイザー・インク | ヘテロアリールスルホンをベースとするコンジュゲーションハンドル、これらの調製のための方法、および抗体薬物コンジュゲートの合成におけるこれらの使用 |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| EP3573995A1 (en) | 2017-01-24 | 2019-12-04 | Pfizer Inc. | Calicheamicin derivatives and antibody drug conjugates thereof |
| EP3630189A4 (en) * | 2017-05-24 | 2021-06-23 | The Board of Regents of The University of Texas System | LINKER FOR ANTIBODY MEDICINAL CONJUGATES |
| AU2018337671B2 (en) | 2017-09-19 | 2021-03-04 | Paul Scherrer Institut | Transglutaminase conjugation method and linker |
| CA3082271A1 (en) * | 2017-11-14 | 2019-05-23 | Debiopharm Research & Manufacturing S.A. | Ligand-drug-conjugates as substrates for selective cleavage by the exopeptidase activity of cathepsin b |
| CN119405833A (zh) | 2018-06-01 | 2025-02-11 | 卫材R&D管理有限公司 | 剪接调节抗体-药物缀合物及其使用方法 |
| CN110468175A (zh) * | 2019-08-22 | 2019-11-19 | 赵秋萍 | 一种复合植物肽粉及其制备方法和用途 |
| MX2022014530A (es) * | 2020-05-20 | 2023-02-27 | Janssen Biotech Inc | Métodos para la conjugación específica del sitio de proteínas que contienen dominios fc glicosilados. |
| US12227593B2 (en) * | 2020-05-20 | 2025-02-18 | Janssen Biotech, Inc. | Site-specific conjugation of glycosylated monoclonal antibodies with transglutaminase |
| KR20230060509A (ko) | 2020-09-04 | 2023-05-04 | 노바록 바이오테라퓨틱스 리미티드 | 넥틴-4 항체 및 이의 용도 |
| WO2022078279A1 (zh) * | 2020-10-12 | 2022-04-21 | 昆山新蕴达生物科技有限公司 | 抗体-药物偶联物及其应用 |
| JP7789396B2 (ja) | 2020-10-25 | 2025-12-22 | アラリス バイオテック アーゲー | 抗体-リンカーコンジュゲートを生成するための手段および方法 |
| KR20240016287A (ko) | 2021-06-01 | 2024-02-06 | 아지노모토 가부시키가이샤 | 항체 및 기능성 물질의 콘쥬게이트 또는 이의 염, 및 이의 제조에 사용되는 화합물 또는 이의 염 |
| EP4422695A1 (en) * | 2021-10-25 | 2024-09-04 | Araris Biotech AG | Methods for producing antibody-linker conjugates |
| WO2025026338A1 (zh) * | 2023-07-31 | 2025-02-06 | 石药集团巨石生物制药有限公司 | 具有高药物负载的抗体-药物缀合物及其用途 |
| US20260078179A1 (en) | 2024-07-18 | 2026-03-19 | Novarock Biotherapeutics, Ltd. | Cdh17 antibodies and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1245217A (en) * | 1981-12-10 | 1988-11-22 | Joshua S. Boger | Renin inhibitory peptides having phe su13 xx deletion |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| US7691962B2 (en) * | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| CN101837130B (zh) * | 2009-03-20 | 2013-10-23 | 北京大学 | 聚乙二醇-二肽-抗肿瘤药物复合物及其用途 |
| US8829033B2 (en) | 2009-09-23 | 2014-09-09 | The University Of North Carolina At Chapel Hill | N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents |
| CA2813411C (en) * | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| SG11201401699WA (en) | 2011-11-11 | 2014-09-26 | Rinat Neuroscience Corp | Antibodies specific for trop-2 and their uses |
| EP2780039B9 (en) * | 2011-11-17 | 2018-04-18 | Pfizer Inc | Cytotoxic peptides and antibody drug conjugates thereof |
| KR20210132742A (ko) * | 2012-12-21 | 2021-11-04 | 알트루바이오 인코퍼레이티드 | 친수성 자기-희생 링커 및 그것의 포합체 |
| US10195289B2 (en) | 2013-07-31 | 2019-02-05 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates using transglutaminase |
| MX371455B (es) * | 2013-08-02 | 2020-01-28 | Pfizer | Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco. |
| SG11201605437YA (en) | 2014-01-27 | 2016-08-30 | Pfizer | Bifunctional cytotoxic agents |
| KR20190072663A (ko) * | 2014-04-25 | 2019-06-25 | 리나트 뉴로사이언스 코프. | 약물이 고도로 로딩된 항체-약물 접합체 |
| CA2951887A1 (en) * | 2014-06-12 | 2015-12-17 | Cspc Dophen Corporation | Homogenous antibody drug conjugates via enzymatic methods |
-
2015
- 2015-08-14 HU HUE15777735A patent/HUE049325T2/hu unknown
- 2015-08-14 PL PL15777735T patent/PL3185908T3/pl unknown
- 2015-08-14 CN CN201580053977.2A patent/CN106795203B/zh active Active
- 2015-08-14 US US15/504,801 patent/US10967068B2/en active Active
- 2015-08-14 SI SI201531244T patent/SI3185908T1/sl unknown
- 2015-08-14 ES ES15777735T patent/ES2797754T3/es active Active
- 2015-08-14 EP EP15777735.0A patent/EP3185908B1/en active Active
- 2015-08-14 RU RU2017104511A patent/RU2680238C2/ru active
- 2015-08-14 AU AU2015308179A patent/AU2015308179B2/en active Active
- 2015-08-14 DK DK15777735.0T patent/DK3185908T3/da active
- 2015-08-14 WO PCT/IB2015/056211 patent/WO2016030791A1/en not_active Ceased
- 2015-08-14 PT PT157777350T patent/PT3185908T/pt unknown
- 2015-08-14 KR KR1020177005202A patent/KR102051503B1/ko active Active
- 2015-08-14 MX MX2017002600A patent/MX384379B/es unknown
- 2015-08-25 CA CA2901684A patent/CA2901684C/en active Active
- 2015-08-26 JP JP2015166643A patent/JP6832621B2/ja active Active
-
2017
- 2017-01-26 IL IL250319A patent/IL250319B/en active IP Right Grant
- 2017-02-27 MX MX2021008334A patent/MX2021008334A/es unknown
-
2021
- 2021-02-02 JP JP2021014690A patent/JP2021073274A/ja active Pending
- 2021-02-23 US US17/183,265 patent/US20210205463A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2901684C (en) | 2020-06-09 |
| MX2017002600A (es) | 2017-05-19 |
| EP3185908A1 (en) | 2017-07-05 |
| US20210205463A1 (en) | 2021-07-08 |
| DK3185908T3 (da) | 2020-06-15 |
| JP6832621B2 (ja) | 2021-02-24 |
| CN106795203A (zh) | 2017-05-31 |
| IL250319A0 (en) | 2017-03-30 |
| IL250319B (en) | 2020-04-30 |
| SI3185908T1 (sl) | 2020-08-31 |
| JP2021073274A (ja) | 2021-05-13 |
| ES2797754T3 (es) | 2020-12-03 |
| PL3185908T3 (pl) | 2020-09-07 |
| JP2016050204A (ja) | 2016-04-11 |
| RU2017104511A (ru) | 2018-09-28 |
| AU2015308179B2 (en) | 2020-07-02 |
| CN106795203B (zh) | 2021-01-26 |
| KR20170036048A (ko) | 2017-03-31 |
| PT3185908T (pt) | 2020-06-18 |
| RU2680238C2 (ru) | 2019-02-18 |
| US20180140714A1 (en) | 2018-05-24 |
| WO2016030791A1 (en) | 2016-03-03 |
| BR112017002912A2 (pt) | 2018-01-30 |
| HUE049325T2 (hu) | 2020-09-28 |
| RU2017104511A3 (es) | 2018-09-28 |
| EP3185908B1 (en) | 2020-04-15 |
| KR102051503B1 (ko) | 2019-12-03 |
| AU2015308179A1 (en) | 2017-02-02 |
| MX2021008334A (es) | 2021-08-05 |
| US10967068B2 (en) | 2021-04-06 |
| CA2901684A1 (en) | 2016-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021008334A (es) | Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco. | |
| CY1124131T1 (el) | Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου | |
| CL2023001909A1 (es) | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo | |
| CY1121750T1 (el) | Cot διαμορφωτες και μεθοδοι χρησης αυτων | |
| MX385585B (es) | Anticuerpos anti-c10orf54 y usos de los mismos. | |
| CL2017002422A1 (es) | Derivados de maitansinoide, conjugados de los mismos, y métodos de uso. | |
| UY36862A (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso | |
| CR20160425A (es) | Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas | |
| CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
| PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
| MX2017004838A (es) | Composiciones de interleucina-15 y usos de estas. | |
| MA40579A (fr) | Anticorps anti-cll-1 et immunoconjugués | |
| CR20160257A (es) | Anticuerpos e inmunoconjugados anti-cd33 | |
| MX385823B (es) | Conjugados de anticuerpo-farmaco hidrofilicos. | |
| EA201691582A1 (ru) | Новые фармацевтические препараты | |
| UY36075A (es) | Derivados de tubulisina | |
| EA201792612A1 (ru) | 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot | |
| MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
| CY1125583T1 (el) | Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv | |
| GT201600252A (es) | Derivados de naftiridinadiona | |
| MX420249B (es) | Agentes de unión monoclonales de cmet, conjugados de fármaco de los mismos y usos de los mismos. | |
| MX373197B (es) | Formulaciones estables de undecanoato de testosterona. | |
| MX2017003949A (es) | Derivados peptidicos novedosos y sus usos. | |
| CY1117740T1 (el) | Χρηση του odiparcil στη θεραπεια μιας μυκοπολυσακχαριδωσης |